DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

To be considered for this study, your cancer must have a specific change in its cells called a ROS1 gene fusion. This must have been found using a special genetic test. Importantly, if you have non-small cell lung cancer, you generally won't be eligible for this particular part of the study, as entrectinib is already approved for that. You'll also need to be able to provide a fresh tissue sample (a biopsy) and blood samples for the research.

Your organs, such as your kidneys and liver, need to be working well enough for you to take part. This will be checked with blood tests. If you are a woman who could become pregnant, you'll need to have a negative pregnancy test and agree to use effective contraception throughout the study. The study is open to both adults and children, as long as they meet the specific health and genetic requirements.

If you decide to join this study, the first step is a 'screening' process. Experts will look at your cancer's genetic information to see if it matches the study's requirements. If it does, you'll have a new biopsy (a small tissue sample taken from your cancer) and give blood samples for further research.

Once enrolled, you'll receive the drug entrectinib. You'll keep taking it either until your cancer starts to grow again, if the side effects become too much to handle, or if you decide you no longer want to participate. Throughout this time, you'll provide more blood samples at different times. After you finish taking the drug, doctors will continue to follow up with you every three months for two years to monitor your health.